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ABSTRACT 
Ischemia Impairs Vasodilation in Skeletal Muscle Resistance Artery 
Kyle Remington Struthers 
 
 Functional vasodilation in arterioles is impaired with chronic ischemia. We 
sought to examine the impact of chronic ischemia and age on skeletal muscle resistance 
artery function. To examine the impact of chronic ischemia, the femoral artery was 
resected from young (2-3mo) and adult (6-7mo) mice and the profunda femoris artery 
diameter was measured at rest and following gracilis muscle contraction 14 days later 
using intravital microscopy. Functional vasodilation was significantly impaired in 
ischemic mice (14.4±4.6% vs. 137.8±14.3%, p<0.0001 n=8) and non-ischemic adult mice 
(103.0±9.4% vs. 137.8±14.3%, p=0.05 n=10). In order to analyze the cellular 
mechanisms of the impairment, a protocol was developed to apply pharmacological 
agents to the experimental preparation while maintaining tissue homeostasis. Endothelial 
and smooth muscle dependent vasodilation were impaired with ischemia, 39.6 ± 13.6% 
vs. 80.5 ± 11.4% and 43.0 ± 11.7% vs. 85.1 ± 10.5%, respectively. From this data, it can 
be supported that smooth muscle dysfunction is the reason for the observed impairment 
in arterial vasodilation.  
 
 
Keywords: Vascular Function, Age, Impaired Vasodilation, Endothelial Dysfunction, 
Ischemia, Arteriogenesis, Mouse, SDF Imaging, Gracilis, Peripheral Artery Disease 
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INTRODUCTION 
CIRCULATORY FUNCTION  
The circulatory system is composed of the heart, which pressurizes the blood, and 
a complex network of blood vessels which deliver nutrients and remove wastes  from 
tissues through the continuous circulation of blood (Figure 1) [1, 2]. Blood flow begins 
in the heart and is pumped through the body by muscular constriction of the left ventricle. 
From the heart, blood enters elastic conduits called arteries (Figure 2). From there, 
arteries stem smaller conduits called arterioles and further down the line these feed into 
capillaries. The venous circulation, venuoles and veins, return blood back to the heart [1]. 
 
 
Figure 1: Circulatory System Anatomy. Diagram showing the heart, arteries, and veins 
of the circulatory system.  
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Figure 2: Vessel Architecture and Function. Diagram showing the direction of flow 
from the heart through the various blood vessels, back to the heart. Adapted from [3]. 
 
Vessel function is determined by tissue structure (Figure 3). Arteries have a large 
amount of elastic tissue which allows them to absorb the large pressure differentials that 
the beating heart creates [1]. The arterioles are responsible for flow control to the distal 
tissues, which is enabled by the large amount of smooth muscle in its medial layer [1]. 
Nutrient exchange is facilitated in capillaries due to their single layer of intimal 
endothelial cells [1].  
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Figure 3: Blood Vessel Anatomy. Diagram shows the various tissue layers in an artery, 
vein and capillary. Adapted from [1]. 
 
The volume of blood in the circulatory system is relatively constant, however the 
distribution of this volume in different regions of the body is highly variable and can be 
altered by factors such as the output of the left ventricle and the contractile state of the 
resistance vessels of these regions [2]. With increased sympathetic activity, blood flow to 
the body increases due to an increased heart rate [1]. It also causes rapid firing of 
sympathetic fibers which innervate the vascular system, causing blood vessels to constrict 
and increase peripheral resistance [1]. 
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In the regions with increased metabolic demand, which causes an increase in 
pCO2, a higher exchange rate is needed due to nutrient consumption and waste formation 
rate [1]. For example, during exercise, muscles require more blood flow to match the 
increase in energy expenditure. This flow control is accomplished by the arterioles, 
located immediately upstream of the capillaries, which increase the lumen diameter by 
relaxation of the surrounding smooth muscle [1]. In metabolically high areas of the body, 
the density of these vessels is greater to allow for more nutrient and waste exchange [2]. 
 The spontaneous, rhythmic contraction of blood vessels, specifically arterioles 
and feed arteries, is involved with regulating blood flow throughout the body  (Figure 4) 
[2].  Vasoactivity serves either of two physiological purposes: regulation of systemic 
blood pressure or redirecting blood flow to different regions of the body [4]. This 
happens through vasoconstriction and vasodilation; which decreases and increases blood 
perfusion to distal tissues respectively [4]. One example of the profound effect 
vasoactivity can have on blood flow is the observation that aerobic exercise can increase 
perfusion nearly 100 times when compared to rest [5]. When working properly, different 
tissues can control the perfusion of their tissue through autoregulation. Autoregulation is 
the ability of tissues to adjust blood flow with regards to the levels of tissue metabolism, 
and vessel pressure [2, 4]. One of the main interests in this area of research is the future 
ability to control vascular function, in regions of dysfunction, through the use of drugs. 
 
 Figure 4: Vasoconstriction and Vasodilation
diameter and vasoconstriction is a decrease in luminal diameter. 
Circulatory Dysfunction 
Blood flow supply 
function, otherwise a medical pathology 
not maintained, increased capillary hydrostatic pressure will cause blood filtration and 
edema1 can occur [2]. If the blood flow is reduced below the proper range
decrease in blood supply to a distal tissue and it becomes ischemic (
Ischemia is insufficient tissue blood flow and results in hypoxia and 
delivery to cells [7]. In healthy tissue, vasodilation appears immediately after the 
beginning of hypoxia and can be maintained for several hours 
vasodilation process is impaired in patients with Peripheral Artery Disease (PAD), and 
the treatment of this dysfunction 
                                                
1
 Edema is a condition in which tissue becomes swollen and puffy due to increased fluid concentrations 
 
. Vasodilation is an increase in luminal 
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to tissues must match metabolic demand to maintain 
occurs. For example, if resistance vessel tone is 
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poor nutrient
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is the motivation for this research [8]. 
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Figure 5: Peripheral Artery Disease (PAD). Peripheral artery disease is a progression 
of atherosclerosis in the distal limbs. It is characterized by a narrowing of the lumen of an 
artery. Adapted from [9]. 
 
PERIPHERAL ARTERY DISEASE 
Ischemic vascular disease is the leading cause of morbidity and mortality in the 
developed world [10]. In the United States alone, PAD affects 8 million adults, a number 
that will more than likely get larger as the population ages [11]. Many factors may lead to 
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this disease, including hypertension, smoking, diabetes mellitus and hypercholesteremia 
[12]. At the cellular level, inflammation and endothelial dysfunction are contributing 
factors to this disease [12-14], and there is general agreement that atherosclerosis begins 
with a damaged or dysfunctioning endothelium [2, 13, 15]. Endothelial dysfunction 
during atherogenesis is characterized by increased expression of adhesion molecules and 
an increased synthesis of inflammatory and pro-thrombotic factors [13]. Adhesion 
molecules enhance the attachment of  monocytes, T lymphocytes, and platelets to the 
endothelium [2]. Once macrophages extravasate into the artery wall, they begin 
modifying the structure of the surrounding smooth muscle cells [2]. Later in the process, 
cholesterol begins to build-up in the sub-endothelial space [14].  
 As this process progresses, the diameter of the lumen of the vessels becomes 
smaller and smaller, known as stenosis. One of the symptoms of this disease is 
intermittent claudication, or ischemic leg pain when the patient walks or climbs stairs [2]. 
With minimal walking, in patients with PAD, the resistance vessels lose the ability to 
become maximally dilated. When the oxygen demand increases with more rapid walking 
or climbing, blood flow cannot increase sufficiently to meet the muscle needs for oxygen, 
and pain caused by muscle ischemia results [2]. It is also thought that the ischemia–
reperfusion injury associated with intermittent claudication could be among the causes 
for increased inflammatory activity and endothelial dysfunction in PAD patients [16]. 
One percent to two percent of PAD patients over the age of 50 develop critical limb 
ischemia (CLI) which begins with pain of the limb at rest and leads to tissue ulcers, 
necrosis and eventually amputation [17]. The one year mortality rate of patients with CLI 
is 20%, and at five years this rate increases to 50% [15]. Clearly, there is a need for 
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treatment of this disease and the goal of this research is to address the problem of 
impaired vasodilation in these patients. 
 
Treatment of PAD 
The goal of contemporary treatments of PAD is to reverse conduit artery stenosis 
and restore tissue blood flow through percutaneous angioplasty or by-pass surgery 
(Figure 6) [18]. Endovascular angioplasty, the process of using a balloon to open up 
occluded arteries in the peripheral vascular system, has been shown to increase flow-
mediated dilation [16]. Another avenue besides surgical treatments is drug therapy. In 
addition to these surgical approaches, endogenous compensation of arterial stenosis 
during PAD can occur through the development of collateral flow paths [18]. Therapeutic 
stimulation of this process has received substantial attention in patients for which surgical 
approaches are ineffective or contraindicated [18]. In order to properly stimulate this 
process, the cellular mechanisms must be fully understood. 
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Figure 6: Angioplasty. Vascular angioplasty involves the insertion of a balloon catheter 
into the stenosed area. The balloon is then inflated to increase the luminal diameter, 
increasing perfusion of downstream tissue. Adapted From [20]. 
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There have been many advances in the understanding of the molecular and 
cellular mechanisms responsible for collateral development [19].  Some of these 
molecules include VEGF, FGF-2, FGF-1 and MCP-1, which have been shown to enhance 
collaterogenesis [19]. Despite our improved understanding of arteriogenesis and 
significant success of preclinical trials, therapeutic vascular growth has not been 
successful in a clinical setting [18, 19]. It is unknown why arteriogenesis therapies have 
not worked, but it could be due to the competing mechanisms of atherosclerosis and 
arteriogenesis [19].  Regardless, it is necessary to study the process more. However, 
collateral growth is a complex remodeling process, and it may be more straight-forward 
to improve vasodilation in these patients. 
 
MECHANISMS OF VASCULAR GROWTH 
 Following an occlusive event, the peripheral circulation remodels in response to 
the altered flow and pressure through vasculogenesis, angiogenesis, and arteriogenesis 
[21]. Vasculogenesis occurs primarily during embryonic development when angioblasts 
differentiate to form primitive capillary plexuses [21], but has been observed in response 
to hindlimb ischemia [22]. The peripheral circulation remodels in response to altered 
flow and pressure through arteriogenesis in response to cellular hypoxia through 
angiogenesis, these processes form collaterals and an expanded exchange network, 
respectively [1, 2].  
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Angiogenesis 
Angiogenesis is the growth of new capillaries from existing capillaries. Although 
angiogenesis can be induced by increased shear stress [23], in the context of ischemia, 
angiogenesis is primarily induced by hypoxia (Figure 7) [18]. Hypoxia increases the 
activity of hypoxia inducible factor-1 (HIF-1), a transcription factor that increases the 
expression of hypoxia-sensitive genes, such as VEGF, which is the most well-studied 
angiogenic factor in the context of both tumor growth and ischemic revascularization 
[18]. Various growth factors, such as VEGF, promote the division of endothelial cells, 
which organize into a hollow tube that sprouts out of the existing capillary. The resulting 
sprouting capillary reconnects to its original capillary branch or a different one, 
completing the angiogenic process [2]. Increasing capillary number will improve 
diffusive transport in the ischemic tissue. However, arteriogenesis affects larger vessels, 
which are more relevant to this work.  
 Figure 7: Angiogenesis
angiogenesis. Not
Arteriogenesis 
Arteriogenesis refers to the transformation of pre
pathways into conduit arteries (
occlusion or a slowly progressing stenosis causes an increase in fluid shear forces on the 
endothelium of the collateral flow path 
ranges between 10 and 70 dyn cm
activates the endothelial cell signaling pathways 
nitric oxide synthase (NOS), platelet
chemoattractant protein-1 (MCP
activity accounts for the vasodilation observed in response to increase
[7]. The elevated shear also causes adhesion molecule
 
. Diagram showing the growth of capillaries through 
e the growth of capillaries from preexisting capillaries.
-existing collateral artery 
Figure 8) [24]. The process begins when a sudden arter
[21]. Normal shear values in arterial circulation 
-2
 [18]. When the range is breached, the elevated shear 
and results in increased transcription of 
-derived growth factor (PDGF) and monocyte 
-1) [21]. The activity of NOS is also incre
d endothelial shear 
 presentation on the luminal surface 
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ial 
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of the endothelium. Adhesion molecules, such as ICAM are necessary to “grab” 
circulating monocytes, which adhere in response to MCP-1 [21]. Monocyte adherence 
potentiates endothelial activation, which causes tumor necrosis factor-α (TNF-α) release, 
further enhancing monocyte adhesion to the endothelium [21]. At the same time, platelets 
adhere to the endothelium and produce interleukin-4 (IL-4), which amplifies the 
expression of adhesion molecules [21].  
 
 
Figure 8: Effects of Shear Stress on Arteriogenesis. The effects of a reperfusion study 
on a rabbit hindlimb. (A) Reperfusion treatment (B) ligation treatment. Image was a post 
mortem angiography. Adapted from [26]. 
 
Once they extravasate, monocytes produce many growth factors, such as 
fibroblast growth factor-2 (FGF-2), which cause mitosis of the endothelial and smooth 
muscle cells [21]. Mast cells, which are converted from basophils, secrete basic fibroblast 
growth factor (bFGF) and vascular endothelial growth factor (VEGF) and may remain in 
the tissue for up to 6 weeks [25]. Finally, matrix-metalloproteinases begin to digest the 
extracellular matrix and provide the space for new cells and enable smooth muscle cells 
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to migrate towards the intima [25]. This generates an inflammatory response that attracts 
T cells which causes smooth muscle cells to undergo apoptotis, creating space for the 
increasing collateral vessel [21, 25]. Those smooth muscle cells that proliferate change 
their phenotype and lose most of their contractile function [25] when they become 
“synthetic”, or proliferative [21]. Once the vessel diameter has increased enough to return 
shear stress back to the baseline levels, arteriogenesis will stop. This process increases 
flow to the downstream tissue until the endothelial cells sense normal shear stress ranges. 
There are several methods of increasing growth of collateral arteries. One of the 
first substances found to increase arteriogenesis was MCP-1 [27]. Unfortunately this 
compound also was shown to be pro-atherogenic, precluding its testing beyond 
preclinical trials (Figure 9) [18, 19].  
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Figure 9: Relation between Collaterogenesis and Atherogenesis. This diagram shows 
pathways that are common to atherogenesis and collaterogenesis. Adapted from [19]. 
 
 Monocytes recruitment can also be improved by granulocyte-monocyte colony 
stimulating factors (GM-CSF) and granulocyte colony stimulator factor (G-CSF) [18], 
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which along with transforming growth factor beta (TGF-β), enhance arteriogenesis [24]. 
Unfortunately, both of these compounds promote tumor angiogenesis and atherosclerosis 
[18].  
 VEGF expression is critical for the presence of collaterals and collateral growth, 
likely through stimulation of endothelial proliferation. Unfortunately, the positive effect 
of VEGF on vascularization in animal models [10, 28] has not been observed in large 
clinical trials [29]. In addition to a lack of efficacy, VEGF therapies are associated with 
edema, due to the ability of VEGF to increase endothelial permeability [19, 24].  
 To diminish these risks of side effects, many efforts have been made to deliver the 
arteriogenic drugs locally [24], rather than intravascularly [18, 30]. Current research 
predicts future methods to deliver these drugs through therapeutic devices such as stents. 
These stents would elute a pro-arteriogenic compound into the affected artery over a 
period of time, mitigating current delivery complications [18, 24]. Additionally, the risk 
factors that cause PAD such as age, hypercholesterolemia, genetic susceptibility, diabetes 
and smoking may also impair the efficacy of these therapeutic interventions [31]. Due to 
the complexity of the arteriogenesis pathway, multiple therapeutic agents or cell-based 
therapies may be needed to achieve efficacy [18, 31].  
Cell based therapies refer to the process of isolating autologous cells and 
delivering them to the patient [32]. Their usefulness, however, has been debated because 
the process of growing collateral arteries is a local and self-sufficient process that is not 
dependent on the circulating stem cells [25]. However, with dysfunction the 
arteriogenesis pathway is broken, so delivering cells that can secrete many cytokines 
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could be an effective modality to stimulate the process. Bone marrow derived progenitor 
cells improve arteriogenesis, but their clinical efficacy remains inconclusive [18, 19]. 
 
MODELS OF ISCHEMIA 
 The main challenge of therapeutic arteriogenesis is there has been a history of 
therapeutic efficacy in animal models followed by disappointing results in blinded and 
randomized clinical trials [18, 31]. While there is no perfect model of PAD, many efforts 
have been made to mimic the symptoms and pathologies of PAD to provide a better idea 
of efficacy of treatments further down the line. [25]. Often these procedures involve  
surgery, which takes a matter of minutes to hours; the time it takes for a human to 
develop an atherosclerotic lesion is years to decades [33]. These inherent differences 
require a better understanding of the animal models that are currently used. Fully 
understanding these differences will help lead to more reasonable interpretations of the 
results. 
Experimental models of PAD can be divided into human and animal models. 
Human models are limited from the perspective that invasive studies cannot be performed 
and long-term studies are difficult. This is due to increased regulation enforced by the 
Food and Drug Administration (FDA), specifically through the Office of Good Clinical 
Practice (OGCP). Even with these difficulties human models are utilized. In one human 
study, arterioles were isolated form amputated limbs for highly controlled studies of 
vascular reactivity [34]. Conversely, non-invasive assessments, such as laser Doppler 
perfusion imaging, can be performed routinely in patients with PAD  [15]. 
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Comparatively, animal models can be used for long-term invasive studies. 
Unfortunately, variability can be introduced through the numerous species and strains of 
animals that can be used. Different types of surgical methods used to induce ischemia 
also increase this variability. There are several experimental assessment endpoints that 
must be addressed to properly analyze the efficacy of a therapy, such as vascular cell 
proliferation, vascular number and size, and blood flow perfusion [35]. Many studies aim 
to look at all of these factors; however there is no standard method to address these 
experimental endpoints. This creates a need to understand the model being used in order 
to develop experiments that properly evaluate the problem or efficacy of the solution. 
 
Mouse and Rat Models 
 One of the most variable and simple of the animal models are rodents. 
Advantages of these animals are their low cost, high reproductive rate, and general 
similarity to human physiology. Historically, rats were the most common, but with the 
emergence of mouse embryonic cell culture and genetic modification, mice have become 
a more popular choice for experiments designed to establish causal relationships [36]. 
Through genetic manipulation, different co-morbidities can be induced, such as 
hypercholesterolemia following the disruption of the genes involved in cholesterol 
trafficking[37].  
For ischemic research, two different surgical techniques are frequently used: 
ligation and resection. During a ligation, the femoral artery is occluded with a suture, 
preventing downstream flow [38]. The result of this occlusion is the enlargement of 
superficial collateral arteries, which can be viewed in vivo one to three weeks after 
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femoral occlusion [38]. A resection surgery involves the removal of the femoral artery 
and all of its branches from the hindlimb [39, 40]. Excision of the femoral artery results 
in occlusion of the external iliac artery; blood flow to the ischemic limb is consequently 
dependent on deep collateral vessels originating from the internal iliac artery [39, 40]. 
Often, a larger rodent model is used, such as a rat, which allows a greater range of 
experimental options with regards to surgical methods [41]. There are still inherent 
differences between the physiology of a human and a rodent. One example is the 
difference between blood type proteins of a mouse and a human [42]. This can be seen on 
the cellular level in embryonic stem cells [42]. This may explain why mice and rats have 
not been predictive of a therapeutic effect on humans. To better match the diseased 
human pathology and anatomy, a large animal model is considered. 
 
Rabbit and Large Animal Models 
 Rabbit models are used for a variety of FDA and international biocompatibility 
testing standards [43],  chiefly in vascular research because their iliac artery diameter is 
comparable to that of the human coronary artery and has similar thrombogenic properties 
[43]. Other than the previously stated advantages, rabbits do not provide many more 
advantages when compared to rats and larger animal models. However, they are used 
frequently in ischemia research. 
The most common ischemia models involve ligations and arteriovenous shunts, 
which can be used to assess revascularizations in the rabbit hindlimb [28]. Arteriovenous 
shunts involve the ligation of both femoral arteries and for the side-to-side anastomosis 
operation of the distal stump of the left femoral artery with the accompanying vein [26]. 
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This surgery re-routes vasculature and causes arterial vessels to drain into veins, which 
have a lower hydrostatic pressure than downstream arterioles and hence causes an 
increased pressure gradient and increased flow, resulting in an increased shear stress [26]. 
Similar to rodent studies, rabbits have predicted safety and positive responses to biologic 
therapeutics [44]. 
 When even larger models are needed, the most commonly used in ischemia 
research are the porcine and canine model. Canines are often used because they are easy 
to train and their circulation contains many collaterals for arteriogenesis research [35, 
45]. The porcine model is advantageous because they can be given a high calorie diet and 
gain similar pathologies to humans with PAD [43]. Animal species, surgical technique, 
treatment and size must all be analyzed in order to improve their predictive capacity in 
humans. Additionally, the differences in animal models can lead to differences in 
responses when comparing across animal models. Thus inferring animal response to 
humans needs to be done with caution and with careful consideration of the potential 
differences. With a history of efficacy of therapies in animal models and inadequate 
results seen in randomized patient trials, a different approach is needed if we want to 
improve distal perfusion in those patients that are suffering from impairment [18, 31]. 
Therefore a better understanding of vascular function is needed. 
 
MECHANISMS OF VASCULAR FUNCTION 
 Collateral growth is a complex process and more effective results could be 
observed and complement or potentially replace therapeutic arteriogenesis by 
determining how to improve vasodilation. As stated previously in the introduction, blood 
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flow is controlled by the increase and decrease of lumen diameter in the resistance 
vasculature, arterioles, and feed arteries [1]. 
 
Vasoconstriction 
 Vasoconstriction involves the constriction of smooth muscle in a blood vessel to 
decrease the luminal diameter and decrease blood velocity and distal perfusion [4]. 
Normally, vessel tone is maintained through constant activity from the sympathetic 
nervous system [2]. Control of the vessel diameter can be divided into three separate 
categories: local, neural, and hormonal mechanisms [4]. One of the most recognizable 
ways of local vasoconstriction is in response to a cold stimulus which is a method of 
preserving core body temperature [2]. Stimulation of this control pathway causes various 
systemic effects, one of which is most relevant to this research, the increasing in 
peripheral resistance through the use of neuroephinephrine [2]. Vessel pressure also has 
an effect on vessel tone due to the myogenic response; vessels constrict in response to 
high pressure [2]. There are several hormones that cause vasoconstriction, such as 
Angiotensin II, which is a potent vasoconstrictor and a systemic way that blood pressure 
is regulated [4]. Just as blood pressure can be increased through vasoconstriction, it can 
be lowered through vasodilation. 
 
Vasodilation 
 Vasodilation involves the relaxation of smooth muscle in a blood vessel to 
increase the luminal diameter and increase blood velocity and distal perfusion [4]. Local 
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factors of vasodilation include substances that are released from the vessel endothelium 
such as prostacyclin (PGI2) and nitric oxide (NO) [2]. Hormonal mechanisms of 
vasodilation include atrial natriuretic peptide which causes vasodilation in the cardiac 
vasculature [4]. Vasodilation in skeletal muscle is known to be regulated by muscle 
metabolism, but to effectively increase flow, there must be coordination with vessels 
outside of the metabolic field, such as feed arteries. This occurs through a mechanism 
known as ascending vasodilation [46].  
 Ascending vasodilation is the process of the “spread” of a vasomotor response 
along a blood vessel [5]. Research has demonstrated that this is due to electrical signals 
that are capable of traveling for millimeters along the arteriolar endothelium [5, 47]. 
Ischemia may impair this process due to the resulting vascular dysfunction [48]. 
 
VASCULAR DYSFUNCTION 
 A healthy resistance vessel should dilate in response to ischemia. When this 
mechanism is dysfunctional, the downstream tissue becomes transiently ischemic  [2], 
producing intermittent claudication. It is also thought that the injury associated with 
intermittent claudication could be among the causes for increased inflammatory activity 
and endothelial dysfunction in PAD patients [16]. One of the most common causes of 
endothelial dysfunction and inflammation is diabetes mellitus [37, 49, 50].  
 Endothelial dysfunction and inflammation in diabetes is due to hyperglycemia and 
it causes a decreased endothelial dependent relaxation due to increased  thromboxane 
receptors, enhancing vasoconstriction [49]. Similarly, endothelial dysfunction observed 
in patients with PAD could be due to impaired endothelial vasodilator responses [11].  
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In patients with chronic limb ischemia, feed arteries from ischemic skeletal 
muscle showed exaggerated vasoconstrictor responses [51]. This was thought to be due to 
an increase in both α-1 and α-2 adrenergic receptors in the ischemic tissue [51]. The goal 
of this research is to better understand this mechanism to create efficacious treatments for 
impaired α-adrenergic receptor responsiveness 
 
Effects of Age 
 Age is one of the greatest risk factors for developing chronic ischemia [52]. Also, 
there are greater numbers of older people in hospitals when compared to younger people 
[53]. The effects of age on the human body are complex and include such as increased 
blood pressure (hypertension) and impaired wound healing [4, 17]. Advanced age also 
reduces muscle mass and increases vascular resistance [54]. Peripheral resistance is 
directly tied to the material properties and the structural presence of blood vessels, which 
changes with hypertension of blood vessels. As people get older, arteries lose their 
elasticity and become stiffer with atherosclerosis and other pathologies [4]. Sympathetic 
nerve activity also increases with age, causing vessels to be more constricted [54]. These 
changes may explain the negative effect of age on arteriogenesis [31].  
 These vascular impairments are recapitulated in animal models, in which VEGF 
expression was reduced in the ischemic limbs of aged mice and rabbits compared to 
young animals [55]. Endothelial dysfunctional could represent a putative basis for age-
dependent impairments in angiogenesis [55]. Further, collateral numbers and endothelial-
dependent vasodilation were reduced in adult mice (6mo of age) [37]. Senescent mice, 
aged 20 months exhibited reduced functional vasodilation, likely due to an increase in 
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concentration of α-adenoreceptors in the microvasculature of an aged mouse [54]. From 
this research, it is hypothesized that endothelial dysfunction is responsible for this 
decrease in vasodilation in an aged, ischemic mouse. 
 
THERAPEUTIC METHODS OF INCREASING VASCULAR FUNCTION 
 One of the only therapies currently known to increase vascular function is 
exercise. Exercise therapy for patients with intermittent claudication increases pain-free 
walking time, maximal walking time and overall physical capacity [41]. PAD patients 
that are more physically active have increased flow-mediated dilation [11]. 
Unfortunately, many patients with PAD are restricted or prevented from participating in 
these supervised exercise programs due to limited ability or lack of medical insurance 
coverage [11]. Additionally, the molecular mechanism of this benefit is not understood, 
consequently its therapeutic efficacy cannot be maximized. Additionally, to fully 
understand how exercise benefits vasodilation, we must understand why vasodilation is 
impaired in the first place. Therefore there is an obligation to discover alternative 
methods of treatment such as drug and surgical intervention. 
 Some drug therapies to increase revascularization have been ineffective and have 
many counterproductive side effects [19]. It is imperative for these new vessels to have 
proper vascular function, unfortunately research has shown otherwise [5]. One possible 
solution to this problem is the mechanism of eNOS. It is thought that eNOS causes an 
increase in endothelial NO production which is a known vasodilator [2], and it has been 
shown to increase skeletal muscle perfusion in a rat model [56]. 
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Despite our improved understanding of arteriogenesis and significant success of 
preclinical trials, therapeutic vascular growth has not been successful in a clinical setting 
[18, 19]. It is unknown why arteriogenesis therapies have not worked, but it could be due 
to the competing mechanisms of atherosclerosis and arteriogenesis [19].  Regardless, it is 
imperative that the mechanism is fully understood in order to properly address the 
problem. More effective results could be observed and complement therapeutic 
arteriogenesis by determining how to improve vasodilation in these patients. Vascular 
function must improve in an ischemic environment, and resolving this problem is the 
basis of this research. 
 
OBJECTIVES AND HYPOTHESIS 
 The goal of this research is to better understand how ischemia affects vascular 
function. This knowledge will help develop more effective therapies in the patient 
population. To achieve this goal, the following Specific Aims were completed: 
 
1. Specific Aim 1 –Test the hypothesis that age will decrease the functional 
vasodilation during ischemia. The objective was to validate previous data on 
3mo old mice, and advancing the data on 6mo old mice. It was also the 
intention to validate results with a different group’s research performed on 
mice at 3 and 6 months [37]. 
2. Specific Aim 2 - Establish a consistent superfused functional vasodilation 
protocol using healthy mice. The goal of this aim was to create a reproducible 
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protocol that allows studies to eventually use pharmacological agents during 
functional vasodilation to assess specific aspects of dysfunction. 
3. Establish an experimental protocol for assessing vascular reactivity using 
pharmacological agents. The purpose of this aim was to explore the vascular 
reactivity to endothelial dependent and smooth muscle dependent 
vasodilators, as well as obtain a vascular range of motion with 
vasoconstrictors. 
4. Test the hypothesis that the ischemic profunda femoris artery will exhibit 
impaired endothelial-dependent vasodilation. The purpose of this aim was to 
explore the vascular reactivity to endothelial dependent and smooth muscle 
dependent vasodilators in response to ischemia, as well as obtain a vascular 
range of motion with vasoconstrictors. 
 
Completing these aims will help further the experimental options of the lab while 
discovering the potential mechanisms of dysfunction when ischemia is present. 
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METHODS 
HUSBANDRY 
All procedures were reviewed and approved by the Institutional Animal Care and 
Use Committee (IACUC) of the California Polytechnic State University in accordance 
with the Guide for the Care and Use of Laboratory Animals. Male C57 mice aged 7-9 
weeks were housed in the Cal Poly vivarium, with four mice to a micro-isolator cage. 
The room was temperature controlled with a 12 hour to 12 hour light-dark cycle. Harlan 
18% protein rodent chow and water were provided ad libitum. During cage changes, 
isolation attire was worn to maintain aseptic conditions. Mice were monitored on a daily 
basis and any notes were taken if irregularities in behavior were noticed. 
 
FEMORAL ARTERY RESECTION PROTOCOL 
Surgeries were performed using a stereomicroscope on male C57 mice under 
sterile conditions using Isoflurane anesthesia (APPENDIX A). The hindlimb area was 
first shaved and removed of hair. Nolvasan was used to disinfect the surgical field and 
reduce the likelihood of infection. The mice were kept at a temperature of ~35 °C using a 
rectal-thermistor controlled heating pad. A sterile drape was placed over the mouse with 
an opening over the surgical area (Figure 10). Figure 11 shows the approximate area of 
femoral artery and vein resected from the hindlimb. The first incision was made with a 
straight cut over the medial thigh of the mouse. The cut was extended proximally until 
the abdominal wall was visible. It was also extended distally to midway between the knee 
and ankle. Sterile saline solution was used to irrigate the incision and prevent tissue 
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desiccation. Connective tissue was blunt dissected over the femoral neurovascular 
bundle. Then, the epigastric fat pad and epigastric artery-vein pair were dissected using 
blunt dissection and heat cauterization.  
 
 
Figure 10: Surgical Setup. Picture showing the surgical suite. The mouse is shown 
underneath the sterile drape. All surgical instruments and objects that touched the mouse 
during surgery were kept sterile to prevent infection. 
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Figure 11: Resected Region. (A) Hindlimb before resection. (B) Hindlimb with resected 
area denoted by a black line. The distal hindlimb area is not fully visible. 
 
Once the fat pad was removed, the femoral artery and vein pair was separated 
from the nerve using gentle blunt dissection. The femoral artery and vein pair was then 
ligated proximal to the profunda femoris with a 6-0 silk suture. The profunda femoris was 
then cauterized as close to the femoral artery and vein pair as possible to minimize 
hemorrhage following femoral artery-vein resection. The femoral artery-vein pair was 
then ligated halfway between the knee and ankle.  Veins branching off of the femoral 
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artery-vein pair were cauterized to leave some native circulation intact. Great care was 
taken by the surgeon to leave as many branches as possible. A cotton swab was used to 
apply counter-pressure on the tissue while the femoral artery vein pair was carefully 
pulled and separated from the underlying tissue and cut just distal to the proximal 
ligation. Finally, the skin incision was closed using 7.0 polypropylene suture, Figure 12. 
.
 
Figure 12: Suture Timeline. (A) Hindlimb before incision is made (B) Hindlimb after 
resection surgery and suturing protocol (C) Hindlimb 14 days after surgery. 
 
 An incision, equivalent in length and placement, was made on the contralateral 
limb. Sterile saline was used to irrigate the incision and prevent tissue desiccation. 
Connective tissue over the femoral neurovascular bundle was blunt dissected similar to 
the previous limb. This was done to create a sham limb, designed to control for any 
effects of general surgical trauma. Finally, the skin incision was closed using 7.0 
polypropylene suture. The mouse was then given a subcutaneous injection of 
buprenorphrine (0.07 mg/kg) and placed in a warm recovery bin until ambulatory, then 
was returned to the vivarium. 
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INTRAVITAL MICROSCOPY WITH FUNCTIONAL VASODILATION PROTOCOL 
 SDF Imaging was used to evaluate profunda femoris artery diameter (APPENDIX 
B). Experimental preparation/dissections were performed using a stereomicroscope. The 
hindlimb area was first shaved and removed of hair and mice were maintained at ~35 °C 
using a rectal-thermistor controlled heating pad. The initial incision was made with a 
straight cut over the medial hindlimb of the mouse. The cut was extended proximally 
until the abdominal wall was visible. Phosphate Buffered Saline (PBS) solution was used 
to keep the incision irrigated and prevent tissue desiccation. Connective tissue was 
carefully dissected away from the leg, as to not harm the underlying muscle. The 
epigastric fat pad was then blunt dissected away from the abdominal wall, and cautery 
was used to bisect the fat pad into two parts. This was done to allow placement of the 
MicroScan over the profunda femoris artery. 
Once the dissection was complete, the MicroScan was then placed over the 
profunda femoris artery and positioned such that the anterior gracilis muscle was visible 
at the bottom of the field of view. Two electrodes were then placed on the mouse 
hindlimb: the ground electrode on the skin of the mouse and stimulating electrode above 
the gracilis muscles (Figure 13). It was important to not puncture the muscle because this 
caused unwanted hemorrhage. To test proper placement, the gracilis muscle was 
stimulated with 1mA square waves 100µs in duration at 1 Hz until proper electrode 
placement was confirmed. If the hindlimb twitched and was visible on the video image, 
proper electrode placement was confirmed. At this point a KimWipe was used to remove 
the remaining PBS solution from the hindlimb. Mineral oil was then placed on the 
hindlimb using a pipette and covered with plastic wrap.  
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Figure 13: Electrode Placement. Areas of interest are labeled. Note the placement of 
the electrodes: on the gracilis muscle and on the skin. A retractor was used to fully show 
the entire hindlimb area. 
 
The mineral oil prevents the tissue from desiccating and creates an effective 
barrier to prevent oxygen diffusion [57]. High pO2 may cause vasoconstriction and alter 
basal tone as well as demand for oxygen. Therefore, to keep a controlled system, an 
environment free from oxygen diffusion is very important. 
 The experimental preparation was allowed to recover for 30 minutes. Following 
this recovery period, a 10 second video baseline measurement was taken. The gracilis 
muscle was then stimulated with 1mA square waves 200µs in duration at 8 Hz for 90 
second. 10 second videos were taken before stimulation, after stimulation, and every two 
minutes afterwards until the resting diameter was reached, ±5µm. The gracilis muscle 
was then stimulated with 1mA square waves 500µs in duration at 8 Hz for 90 seconds. 
Again, 10 second videos were taken before stimulation, after stimulation, and every two 
minutes afterwards until the baseline diameter was measured. After both stimulation 
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protocols were complete, the hindlimb was covered with plastic wrap and the process was 
repeated on the contralateral limb; the order of measurement was randomized between 
the two limbs. This was done to prevent experimental error that was found when limb 
order was not randomized [58]. After the protocol was completed on both limbs, the 
mouse was euthanized by cervical dislocation. Sacrificed mice were stored in a -20°C 
freezer and disposed in a biohazard waste container. 
 
INTRAVITAL MICROSCOPY WITH SUPERFUSION PROTOCOL 
In order to test the effects of pharmacological agents on the current model, a 
method to apply them to the preparation without the use of mineral oil was needed. 
Therefore a superfusion protocol was proposed (APPENDIX C). The superfusion 
solution was a physiological salt solution (PSS) composed of the following compounds 
(in mM): NaCl 137, KCl 4.7, MgSO4 1.2, CaCaL2 2, and NaHCO3 18. Prior to each 
experiment, the PSS was warmed in a water bath at 45°C and deoxygenated/pH-balanced 
by bubbling with a 95%:5% N2:CO2 mixture for approximately 15 minutes. After the 
solution was prepared, a portion of the liquid was poured into the superfusion circuit 
(Figure 14). 
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Figure 14: Superfusion Circuit. Diagrams of the circuit used to apply superfusion 
solution on the hindlimb of the mouse. (A) Basic block diagram of the circuit (B) Image 
of the actual circuit used in experiments. 
 
SDF Imaging was again used to evaluate the diameter of the profunda femoris 
artery, and the animal was prepared as described above. Once the dissection was 
complete, the MicroScan was then placed over the profunda femoris artery and 
positioned with the gracilis muscle at the bottom of the field-of-view. Superfusion 
solution was adjusted to flow at ~2mL·min-1 and a thermistor was used to ensure that a 
temperature of 35°C was maintained.  
The limb was then allowed to recover for 30 minutes from the dissection. 
Following this recovery period, a 10 second video baseline measurement was taken 
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before the addition of pharmacological agents in the following order: neuroepinephrine 
(10-4M), acetylcholine (10-4M), and sodium nitroprusside (SNP) (10-4M). Agents were 
allowed to flow over the experimental preparation for 5 minutes; 10 second videos were 
taken within the last minute. After the protocol was complete, the hindlimb was covered 
with plastic wrap and the process was repeated on the contralateral limb. The order of 
experimentation was alternated between the right and left hindlimbs for each mouse [58]. 
After the protocol was completed on both limbs, the mouse was euthanized by cervical 
dislocation. Sacrificed mice were stored in a -20°C freezer and disposed of in a biohazard 
waste container. 
 
DRUG MECHANSIMS OF ACTION 
Norepinephrine 
Norepinephrine is one of the most important regulators of vasoconstriction in 
skeletal muscle resistance vessels [1]. Norepinephrine is a catecholamine, which is a class 
of amines that act as chemical transmitters [1], other examples include epinephrine and 
dopamine [1]. In a stressful situation, neuroepinephrine is synthesized from tyrosine and 
is secreted from sympathetic neurons that synapse on the smooth muscle [1].  Smooth 
muscle cells then have different receptors that receive the neurotransmitter. Specifically 
α1-adenoreceptors and α2-adenoreceptor and β-adenoreceptors [2], arterial 
vasoconstriction is predominantly mediated by α1-adenoreceptors with a small 
contribution from α2-adenoreceptors [34]. Previous studies have shown an increase in 
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certain receptors due to ischemia, thus the motivation for using this drug in the research 
[34]. Figure 15 shows the cellular mechanism of this endogenous neurotransmitter. 
 
 
Figure 15: Neuroepinephrine Pathway. Concept map showing the cellular mechanism 
of neuroepinephrine. It binds to specific receptors and results in smooth muscle 
contraction, or in the case of blood vessels, vasoconstriction. 
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Acetylcholine 
Acetylcholine is a neurotransmitter that is released by nerve endings, specifically 
the cholinergic fibers (Figure 16) [1]. Acetylcholine receptors are found on the 
endothelial cell and when activated result in vasodilation [59, 60]. This compound is 
typically used in order to assess endothelial dysfunction in vasodilation due to its ability 
to produce a robust dilation that is endothelial dependent, which was the main motivation 
in using this drug in the protocol [55]. However, there has been some debate regarding 
this due to a group that showed that vasodilatory chemicals may act differently than the 
natural pathway [61].  
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Figure 16: Acetylcholine Pathway. Concept map showing the cellular mechanism of 
acetylcholine. The process begins with acetylcholine binding to a cholinergic receptor 
and results in vessel vasodilation. This is an endothelial dependent vasodilator. 
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Sodium Nitroprusside 
This mechanism is very similar to acetylcholine; only it completely skips the 
endothelial process and goes directly to giving rise to stimulating sGC (Figure 17). NO 
donors are typically used to assess smooth muscle functionality due to its mechanism, 
which was the main motivation for using this drug in the study [55]. Nitrates are also 
used as treatments for angina and cardiac ischemia in order to achieve greater blood flow 
in the heart [62].  
 
Figure 17: Sodium Nitroprusside Pathway. Concept map showing the cellular 
mechanism of sodium nitroprusside. It begins with the donation of nitric oxide to the 
smooth muscle cell, which results in vasodilation of the vessel. This is a smooth muscle 
dependent vasodilator. 
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SUPERFUSION PLUS FUNCTIONAL VASODILATION PROTOCOL  
 Superfusion intravital microscopy was performed as described above, with the 
following modification (APPENDIX D). Once the MicroScan was placed over the 
profunda femoris artery, a ground electrode and placed on the skin and a stimulating 
electrode was placed above the gracilis muscles. Proper placement was confirmed with 
test contractions and the superfusion solution was adjusted to ~2mL·min-1.  
After the 30-minute recovery period, the gracilis muscle was stimulated with 1mA 
square waves for 200µs or 500µs in duration at 8 Hz for 90 seconds. Ten-second videos 
were taken before stimulation, after stimulation, and every two minutes afterwards until 
baseline diameter was measured. After both stimulation protocols were complete, the 
hindlimb was covered with plastic wrap and the process was repeated on the contralateral 
limb. The order of experimentation was alternated between the right and left hindlimbs 
for each mouse [58]. After the protocol was completed on both limbs, the mouse was 
euthanized by cervical dislocation. Sacrificed mice were stored in a -20°C freezer and 
disposed of in a biohazard waste container.  
 
IMAGING AND STATISTICAL ANALYSIS 
 Automated Vascular Analysis (AVA) was used to measure diameters from 
stabilized videos (APPENDIX E). Data was analyzed using the statistics package in 
Microsoft Excel. Paired t-tests were used for data sets that showed a linear association 
which was indicative of dependence between the two sets of data. This was true for all 
data sets in the first Aim except for when comparing between adult and young mice, in 
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which a one-way ANOVA was used. In Aims three and four, groups were compared by 
using a one-way ANOVA. Summary data are represented as mean values ± standard 
error.  
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RESULTS 
EFFECTS OF AGE & ISCHEMIA ON FUNCTIONAL VASODILATION 
For Specific Aim 1 (Page 26), the hypothesis that age and ischemia reduce 
functional vasodilation in the profunda femoris feed artery was tested. It was 
hypothesized that the effects of these treatments would be additive, which was tested by 
comparing age and ischemia individually against a control. Arteries were measured as 
stated in the methods section (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
Figure 18: Example of Profunda Femoris Measurements. 
the profunda femoris artery (lighter color) on the hindlimb of the mouse. Taken at 
different time points (A) Sham artery before stimulation. (B) Sham artery after 200 µs 
stimulation, note increase in diameter. (C) Sham artery after 500 µs stimulation, note 
smaller increase in diameter. (D) Experimental artery before stimulation. (E) 
Experimental artery after 200 µs stimulation, note increase in diameter. (F) Experimental 
artery after 500 µs stimulation, note smaller increase in diameter
 
A 
B 
C 
Microscan images taken of 
D 
E 
F 
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Impact of Ischemia 
In young mice (2-3mo), the resting ischemic artery was significantly larger than 
the control artery, 103.1 ± 10.3 µm vs. 54.1 ± 3.6 µm, p= 0.0006 (n=8), (Figure 19). 
However, arterial diameter was not different between ischemic and control arteries 
following functional vasodilation (Table 1). Therefore, percent change in diameter 
compared to resting state was examined as the more accurate indicator of vascular 
reactivity (Figure 20). When the gracilis muscles were stimulated with 200 µs duration 
square waves, control arteries dilated significantly more than ischemic arteries, 104.1 ± 
13.0% vs. 15.2 ± 5.0%, p<0.001, (n=8) (Figure 20). When the gracilis muscles were 
stimulated with 500 µs duration square waves, control arteries dilated significantly more 
than ischemic arteries, 137.8 ± 14.3% vs. 14.4 ± 4.6%, p<0.0001 (n=8).  
 
 
Figure 19: Young Ischemic vs. Young Sham. A bar graph of the profunda femoris 
artery diameter during rest, after a 200 µs stimulation and 500µs stimulation *p=0.004 
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Table 1: Ischemia Data Table (Young Mice). Average values taken from functional 
vasodilation protocol with young mice (2-3mo), p value < 0.5 is significant 
 
 Young Sham  Young 
Ischemic  
p value 
Rest 
 
 
54.1 ± 3.6 µm 103.1 ± 10.3 µm 0.0006 
Moderate Contraction 
(200µs duration) 
 
108.3 ± 6.0 µm 116.8 ± 10.0 µm 0.48 
Intense Contraction 
(500µs duration) 
 
125.8 ± 4.6 µm 117.0 ± 11.7 µm 0.50 
Rest vs. Post 200µs 
Stimulation % Change 
 
104.1 ± 13.0 % 15.2 ± 5.0 % 0.0002 
Rest vs. Post 500µs 
Stimulation % Change 
 
137.8 ± 14.3 % 14.4 ± 4.6 % 0.00003 
 
 
 
Figure 20: Young Ischemic vs. Young Sham % Change. A bar graph of the profunda 
femoris artery diameter percent change comparing post 200 µs stimulation to rest and 
post 500 µs stimulation to rest *p<0.001 ×p<0.0001 
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Impact of Age  
To test a corollary of the main hypothesis for this aim, the impact of age alone on 
function vasodilation was examined. There was a trend towards a larger resting diameter 
in the adult mice, 62.4 ± 4.9 µm vs. 54.1 ± 3.6 µm, this difference did not achieve 
statistical significance, p=0.21 (n=10/8) (Figure 21). However, arterial diameter was not 
different between young and adult arteries following functional vasodilation (Table 2). 
Therefore, percent change in diameter compared to the resting state was examined as the 
more accurate indicator of vascular reactivity (Figure 22). When the gracilis muscles 
were stimulated with 200 µs duration square waves, there was a trend towards larger 
young artery dilation, 104.1 ± 13.0% vs. 79.8 ± 11.9%, this difference did not achieve 
statistical significance, p=0.19 (n=8/10) (Figure 22). When the gracilis muscles were 
stimulated with 500 µs duration square waves, young arteries dilated significantly more 
than adult arteries, 137.8 ± 14.3% vs. 103.0 ± 9.4 %, p=0.05 (n=8/10). 
 
Figure 21: Adult Sham vs. Young Sham. A bar graph of the profunda femoris artery 
diameter. Note the increase in adult resting diameter compared to the young resting 
diameter. 
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Table 2: Age Data Table (Sham Limb). Average values taken from functional 
vasodilation protocol with adult mice (6-7mo) and young mice (2-3mo) from the sham 
limb, p value < 0.5 is significant 
 
 Young Sham  Adult Sham  p value 
Rest 
 
 
54.1 ± 3.6 µm 62.4 ± 4.9 µm 0.21 
Moderate Contraction 
(200µs duration) 
 
108.3 ± 6.0 µm 108.0 ± 5.5 µm 0.98 
Intense Contraction 
(500µs duration) 
 
125.8 ± 4.6 µm 123.8 ± 7.8 µm 0.84 
Rest vs. Post 200µs 
Stimulation % Change 
 
104.1 ± 13.0 % 79.8 ± 11.9 % 0.19 
Rest vs. Post 500µs 
Stimulation % Change 
 
137.8 ± 14.3 % 103.0 ± 9.4 % 0.05 
 
 
Figure 22: Adult Sham vs. Young Sham % Change. A bar graph of the profunda 
femoris artery diameter percent change comparing post 200 µs stimulation to rest and 
post 500 µs stimulation to rest. Note the increase in adult resting diameter compared to 
the young resting diameter. *p=0.05 
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Impact of Age and Ischemia 
A similar pattern of profunda femoris diameters was observed in adult mice (6-
7mo). The resting ischemic artery was significantly larger than the control artery, 102.9 ± 
10.3 µm vs. 62.4 ± 4.9 µm, p=0.004 (n=10), (Figure 23). However, arterial diameter was 
not different between ischemic and control arteries following functional vasodilation 
(Table 3). Therefore, percent change in diameter compared to the resting state was 
examined as the more accurate indicator of vascular reactivity (Figure 24). When the 
gracilis muscles were stimulated with 200 µs duration square waves, control arteries 
dilated significantly more than ischemic arteries, 79.8 ± 11.9% vs. 7.6 ± 3.4%, p 
<0.00001 (n=10) (Figure 24). When the gracilis muscles were stimulated with 500 µs 
duration square waves, control arteries dilated significantly more than ischemic arteries, 
103.0 ± 9.4% vs. 16.8 ± 5.9%, p=0.000002 (n=10). Age did not affect the resting 
diameter or functional vasodilation of the ischemic artery (Table 4, Figure 25, and 
Figure 26). 
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Figure 23: Adult Ischemic vs. Adult Sham. A bar graph of the profunda femoris artery 
diameter during rest, after a 200 µs stimulation and 500µs stimulation *p=0.0006 
 
Table 3: Age and Ischemia Data Table (Adult Mice). Average values taken from 
functional vasodilation protocol with adult mice (6-7mo). Chart shows average vessel 
diameters and percent change from rest at rest, moderate contraction and intense 
contraction. p value < 0.5 is significant. 
 
 Adult Sham  Adult 
Ischemic  
p value 
Rest 
 
 
62.4 ± 4.9 µm 102.9 ± 10.3 µm 0.004 
Moderate Contraction 
(200µs duration) 
 
108.0 ± 5.5 µm 111.8 ± 12.2 µm 0.78 
Intense Contraction 
(500µs duration) 
 
123.8 ± 7.8 µm 119.2 ± 12.2 µm 0.75 
Rest vs. Post 200µs 
Stimulation % Change 
 
79.8 ± 11.9 % 7.6 ± 3.4 % 0.00003 
Rest vs. Post 500µs 
Stimulation % Change 
 
103.0 ± 9.4 % 16.8 ± 5.9 % 0.000002 
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Figure 24: Adult Ischemic vs. Adult Sham % Change. A bar graph of the profunda 
femoris artery diameter percent change in adult mice comparing post 200 µs stimulation 
to rest and post 500 µs stimulation to rest *p<0.0001 ×p<0.00001 
 
Table 4: Age and Ischemia Data Table (Young and Adult Mice). Average values 
taken from functional vasodilation protocol with young mice (2-3mo) and adult mice (6-
7mo). Chart shows average vessel diameters and percent change from rest at rest, 
moderate contraction and intense contraction. p value < 0.5 is significant 
 
 Young 
Ischemic  
Adult 
Ischemic  
p value 
Rest 
 
 
103.1 ± 10.3 µm 102.9 ± 10.3 µm 0.99 
Moderate Contraction 
(200µs duration) 
 
116.8 ± 10.0 µm 111.8 ± 12.2 µm 0.77 
Intense Contraction 
(500µs duration) 
 
117.0 ± 11.7 µm 119.2 ± 12.2 µm 0.90 
Rest vs. Post 200µs 
Stimulation % Change 
 
15.2 ± 5.0 % 7.6 ± 3.4 % 0.21 
Rest vs. Post 500µs 
Stimulation % Change 
 
14.4 ± 4.6 % 16.8 ± 5.9 % 0.76 
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Figure 25: Adult Ischemic vs. Young Ischemic. A bar graph of the profunda femoris 
artery diameter averages in adult and young ischemic mice. No clear difference was seen. 
 
 
 
Figure 26: Adult Ischemic vs. Young Ischemic % Change. A bar graph of the 
profunda femoris artery diameter percent change in young and adult ischemic mice 
comparing post 200 µs stimulation to rest and post 500 µs stimulation to rest. 
 
0
20
40
60
80
100
120
140
Rest 200us 500us
P
ro
fu
n
d
a
 F
e
m
o
ri
s 
D
ia
m
e
te
r 
(u
m
)
Adult Ischemic vs. Young Ischemic
Adult
Young
0
5
10
15
20
25
200us 500us
P
e
rc
e
n
t 
In
cr
e
a
se
 i
n
 P
ro
fu
n
d
a
 
F
e
m
o
ri
s 
D
ia
m
e
te
r
Adult Ischemic vs. Young Ischemic % 
Change
Adult
Young
52 
 
SUPERFUSED FUNCTIONAL VASODILATION PROTOCOL 
For Specific Aim 2 (Page 26), a protocol was developed for a superfused 
functional vasodilation. This was completed to eventually test the effects of 
pharmacological agents on the current model during a functional vasodilation protocol. 
This protocol solves the problem of not being able to add drugs to the preparation 
through mineral oil. By adding the drugs to a superfusion solution, pharmacological 
agents can be easily added to the preparation. The goal was to create a consistent protocol 
with minimal dilation caused by the superfusion solution. 
No significant difference in diameter was noticed between the right and left limb 
(Figure 27, Table 5). However, arterial diameter increased following the addition of the 
superfusion solution 89.7 ± 11.3 µm vs. 50.4 ± 6.8 µm, p=0.0007 (n=10) (Table 6). 
Looking at percent change in diameter, vascular reactivity to the superfusion solution was 
more accurately examined (Figure 28). Following the addition of the superfusion 
solution, arterial diameter increased 84.3 ± 13.0% for the left limb and 65.6 ± 17.2% for 
the right limb.  
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Figure 27: Superfused Functional Vasodilation: Right vs. Left Comparison. 
Profunda femoris artery diameter measurements at rest, 30 minutes after superfusion 
solution was applied, and after a 500 µs stimulation. No significant differences were 
observed between right and left limbs. 
 
Table 5: Superfused Functional Vasodilation Data Table. Average values taken from 
superfused functional vasodilation protocol. Chart shows average vessel diameters and 
percent change from rest at rest, moderate contraction and intense contraction. 
 
 Left Limb  Right Limb  
Rest 
 
50.4 ± 6.8 µm 56.6 ± 4.7 µm 
Post Superfusion 
 
89.7 ± 11.3 µm 89.9 ± 9.0 µm 
Post Stimulation 
 
101.5 ± 9.6 µm 112.6 ± 5.7 µm 
Rest vs. Post 
Superfusion % Change 84.3 ± 13.0 % 65.6 ± 17.2 % 
Rest vs. Post 
Stimulation % Change 116.0 ± 16.6 % 108.0 ± 14.0 % 
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Table 6: Superfused Functional Vasodilation Data Analysis Table. Statistical analysis 
of data in Table 5 n=10 
 
 Left Limb 
p values 
Right Limb 
p values 
Rest vs. Post 
Superfusion 
 
0.0007 0.003 
Post Superfusion vs. 
Post Stimulation 
 
0.04 0.004 
Rest vs. Post 
Stimulation 
 
0.00001 0.00000009 
% Change 
 
 
0.07 0.004 
 
 
 
Figure 28: Superfused Functional Vasodilation: Right vs. Left % Change 
Comparison. Profunda femoris artery diameter percent change measurements. No 
significant differences were observed between right and left limbs. 
 
0
20
40
60
80
100
120
140
Post Stim
P
e
rc
e
n
t 
ch
a
n
g
e
 i
n
 p
ro
fu
n
d
a
   
  
  
  
  
fe
m
o
ri
s 
d
ia
m
te
r
Superfused Functional Vasodilation: 
Right vs. Left % Change
Left
Right
55 
 
SUPERFUSED VASOACTIVE AGENTS PROTOCOL 
For Specific Aim 3 (Page 26), a protocol was developed for superfusing 
vasoactive agents. This was completed to test the effects of pharmacological agents on 
the current model by creating a method to apply them to the preparation without the use 
of mineral oil. Previous work completed by this lab (Thomas Kessler) resulted in a 
protocol for the use of two different drugs, Ach and SNP. The goal of this protocol was to 
assess the potency of NE and examine the feasibility of using three different drugs in one 
superfusion experiment. First, a dose response curve to NE was generated (Figure 29). 
No significant difference between limbs was observed (Table 7).  
 
 
Figure 29: Dose Response Curve to Neuroepinephrine. A plot of the diameters of the 
profunda femoris artery with increasing doses of NE (in M). Note that the final dose is 
KCl, a potent vasoconstrictor. No significant difference was found between limbs. 
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Table 7: NE Dose Response Curve. Average values taken from superfusion protocol, p 
value < 0.5 is significant 
 
 Left Limb  Right Limb  p value 
Rest 
 
110 ± 6 µm 105 ± 20 µm 0.78 
10-8 M NE 
 
107 ± 4 µm 106± 21 µm 0.98 
10-7 M NE 
 
105 ± 2 µm 106 ± 23 µm 0.96 
10-6 M NE 
 
108 ± 3 µm 105 ± 18 µm 0.87 
10-5 M NE 
 
106 ± 2 µm 102 ± 16 µm 0.82 
10-4 M NE 
 
41 ± 15 µm 66 ± 29 µm 0.32 
10-4 M KCl 
 
42 ± 9 µm 47 ± 12 µm 0.34 
 
No significant was noticed between limbs for the protocol setup (Figure 30, 
Figure 31). Due to the large difference in diameter between ACh/SNP and NE, dynamic 
range was calculated. No significant difference between limbs was noticed (Figure 32). 
Because no significant differences were found between all groups, the protocol was 
completed with sham and experimental groups. 
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Figure 30: Superfusion: Right vs. Left. A bar graph of the profunda femoris artery 
diameter and its response to three vasoactive agents: NE, Ach, and SNP. No significant 
difference was found between limbs. 
 
 
Figure 31: Superfusion: Right vs. Left % Change. A bar graph of the profunda femoris 
artery diameter percent change compared to resting diameter and its response to three 
vasoactive agents: NE, Ach, and SNP. No significant difference was found between 
limbs. 
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Figure 32: Superfusion Dynamic Range. Dynamic ranges of the right and left limb. 
The maximum was determined from the value of the SNP diameter and the minimum 
from the NE diameter. No significant difference was found between limbs. 
 
EFFECTS OF ISCHEMIA ON ENDOTHELIAL AND SMOOTH MUSCLE 
DEPENDENT REACTIVITY 
For Specific Aim 4 (Page 26), the hypothesis that ischemia reduces vascular 
reactivity in the profunda femoris feed artery was tested. It was hypothesized that the 
cause of this difference would be endothelial dysfunction.  
There was no trend or significant difference noticed between the ischemic and 
sham limbs for both the resting and NE diameters (Figure 33). There was a trend towards 
a larger diameter in the sham artery when superfused with ACh, 133.8 ± 7.5 µm vs. 109.6 
± 12.3 µm, this difference did not achieve statistical significance, p=0.12 (n=8). A similar 
trend was seen with SNP, 137.5 ± 7.6 µm vs. 113.3 ± 12.7 µm, this difference did not 
achieve statistical significance, p=0.12 (n=8). Due to the lack of significance, percent 
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change in diameter compared to the resting state was examined as the more accurate 
indicator of vascular reactivity (Figure 34). Again, when superfused with NE, no 
significance was noticed between groups. When the hindlimb was superfused with ACh, 
control arteries dilated significantly more than ischemic arteries, 80.5 ± 11.4% vs. 39.6 ± 
13.6%, p=0.04, (n=8). When the hindlimb was superfused with SNP, control arteries 
dilated significantly more than ischemic arteries, 85.1 ± 10.5% vs. 43.0 ± 11.7%, p=0.02, 
(n=8). When dynamic range was calculated, the control arteries had a significantly larger 
range, 112.4 ± 6.9 µm vs. 87.5 ± 9.4 µm, p=0.05, (n=8) (Figure 19).  
 
 
Figure 33: Ischemic vs. Sham Superfusion Response. A bar graph of the profunda 
femoris artery diameter and its response to three vasoactive agents: NE, Ach, and SNP. 
No significant difference was found between limbs; however a trend was noticed for ACh 
and SNP between groups. 
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Figure 34: Ischemic vs. Sham % Change. A bar graph of the profunda femoris artery 
diameter percent change compared to resting diameter and its response to three 
vasoactive agents: NE, Ach, and SNP. A significant difference was observed between 
ischemic and sham groups for the ACh percent change and SNP percent change *p<0.05 
 
 
Figure 35: Dynamic Range. Dynamic ranges of the ischemic and sham limb. The 
maximum was determined from the value of the SNP diameter and the minimum from 
the NE diameter. A significant difference was observed between ischemic and sham 
groups *p=0.05. 
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DISCUSSION 
RESTATEMENT OF EXPERIMENTAL OBJECTIVES 
To help guide the discussion of experimental results, the primary objectives of the thesis 
are listed below: 
1. Test the hypothesis that age will decrease the functional vasodilation during 
ischemia. 
2.  Establish a consistent superfused functional vasodilation protocol using healthy 
mice. 
3. Establish an experimental protocol for assessing vascular reactivity using 
pharmacological agents. 
4. Test the hypothesis that the ischemic profunda femoris artery will exhibit 
impaired endothelial-dependent vasodilation. 
 
AIM 1: IMPACT OF AGE ON FUNCTIONAL VASODILATION 
 Age is one of the greatest risk factors for developing chronic ischemia [52]. 
Systemic pathologies such as hypertension and impaired wound healing are also present 
with advanced age [4, 17, 54]. One of the most pertinent effects of age, with regards to 
this research, is its negative effect on revascularization, which have been recapitulated in 
animal models [37, 54]. Acetylcholine-dependent dilation in vitro can be impaired as 
early as 6 months of age [37], while in vivo functional vasodilation is known to be 
decreased in mice of advanced age, 20 months [54]. Given the impact of age on 
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vasodilation we hypothesized that age plus ischemia would have an additive effect on 
reducing functional vasodilation.  
 
Aim 1: Impact of Age on Functional Vasodilation 
 Age reduced the functional vasodilation response observed in the sham limb. In 
young mice, the profunda femoris dilated 140% in response to 500 µs pulses vs. 100% in 
adult mice. Furthermore, the young profunda femoris artery showed a non-significant 
trend of a lower resting diameter 54 µm, compared to 62 µm in the adult animal. This 
was similar to values from previous research, in which adult C57 mice exhibited less 
resting tone than young C57 mice [37]. It was observed that the average weight of the 
young mice was ~20g and that of the older mice was ~30g. There was also a considerably 
higher amount of visible adipose tissue around the artery in the adult mice compared to 
the young mice. Adipose tissue has been shown to increase vessel relaxation due to 
adipocyte-derived relaxing factor (ADRF) [63], opens K+ channels in vascular smooth 
muscle cells [64]. Therefore, an increase in adiposity may explain the lower resting tone 
observed in the adult mice. 
 
Aim 1: Impact of Ischemia and Age on Functional Vasodilation 
Ischemia impaired functional vasodilation in both young and adult mice with only 
10-15% increase in diameter of the ischemic leg, compared to 100-140% for the sham 
limb. Ischemia causes cells to release vasoactive products such as NO [65]. The response 
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to this hypoxia such as molecule concentration and duration, depends upon degree and 
duration of the hypoxic injury [7]. The ischemia surgery induces a significant amount of 
inflammation, which was visually assessed through the observation of connective tissue 
over the surgical site after 14 days. Even though it is such a long time after an 
inflammatory response, the mouse could have aggravated the inflammatory response 
through scratching or biting of the surgical area during the 14 days of recovery. Several 
mice bit off their tails after 14 days; this could be due to the pain at the surgical site, 
however great efforts were taken to mitigate this through an injection of buprenorphrine 
after surgery. Increased monocyte recruitment to the area due to the inflammation could 
have led to a larger resting diameter through the release of vasodilatory factors.  
 Due to the significantly different vasodilatory response between the sham and 
ischemic arteries, the increase in diameter could also be attributed to improper surgical 
technique. The only time the profunda femoris artery was touched during the resection 
surgery was when the artery and vein pair was cauterized as proximal to the femoral 
artery as possible. One of the problems with using cautery is heat propagation through the 
surrounding tissue [66]. When heat propagates through a tissue, it causes cellular 
temperature to rise, leading to death of the cell. If the heat propagates too far or gets too 
hot, less viable tissue remains. Thus, with increased heat propagation, a smaller section of 
artery can be analyzed 14 days later. Also, this heat could have propagated into the artery 
and caused a significant amount of endothelial dysfunction, creating a difference in 
diameter. Heat ablation causes intimal thickening as well as activation of the coagulation 
cascade, which is “dose dependent”; meaning a larger amount of heat application from 
the cautery would increase the negative effects [67, 68]. Due to the fact that the heat 
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cautery is battery operated, the actual temperature of the cautery tip, and the time spent 
cauterizing the artery was variable for each surgery. If the cautery tip was left near the 
tissue for too long, the surrounding area would become burnt and charred. This occurred 
only a few times, but was the result of improper cautery equipment or technique. Extra 
effort was made to make sure that this never happened to the tissue; however the variable 
cautery temperatures made this difficult. After a new cautery was acquired, resting 
diameters and tissue charring decreased. 
Another possible explanation for the increased artery diameter, which may have 
reduced the dynamic range and dilation potential of the vessel, is the tissue dissection 
technique of the ischemic limb before the intravital microscope and microelectrodes were 
placed. If there was a significant inflammatory response to the surgery, there was a 
significant amount of connective tissue that needed to be dissected in order to clearly 
visualize the artery. Even if it was visible through the light microscope, a layer of 
connective tissue on top of the profunda femoris artery could prevent successful focusing 
of the intravital microscope. Also, if the tissue around the artery was agitated during 
dissection, this could have injured and dilated the profunda femoris artery. Extra care was 
taken to ensure that the connective tissue was carefully dissected away from the artery 
before measurements were taken. 
Several other precautions were taken during the experiment in order to maintain 
consistency between subjects. The ischemic and sham legs measurements were alternated 
as recommended by a previous researcher in the lab, Matt Yocum [58]. Even with efforts 
to improve consistency, there was still a significant difference between the two groups. 
This further supports the theory that the surgery affected the artery in some way. 
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The result of a high resting diameter was most likely due to the cautery and 
surgical/dissection technique. After performing several surgeries and dissections, my 
technique and consistency improved. Additionally, with the acquisition of the new 
cautery, the issue of large resting diameters disappeared.  
 
Aim 1: Future Recommendations 
Several problems were observed with the current imaging protocol. As previously 
mentioned, the MicroScan intravital microscope has an immersion lens, leaving very 
little space between the microscope tip and underlying tissue. Contact between these two 
surfaces may irritate the artery and cause it to dilate.  Also, due to the nature of the 
surgery that is used and the experimental model, finding a clear picture of the artery is 
sometimes difficult (Figure 36). An elevated inflammatory response due to surgical 
trauma can cause a buildup of connective tissue and/or increase vascularization. This 
causes a reduction in image clarity and sometimes vascular response to stimulus. 
Furthermore, with older or larger mice, increased adipose tissue can cause similar 
difficulties. 
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 For future researchers interested in assessing the impact of age and ischemia on 
vasodilation, several topics must be analyzed further. Further research is needed to 
determine why there was a significant difference between resting diameters in the 
experimental and sham profunda femoris. By using a superfusion setup, pharmacological 
agents can be added to the artery and help further explain the cellular pathways that could 
be dysfunctional. First, this experiment should be repeated using the proper cautery to 
potentially eliminate that variable. Eventually, pharmacological inhibitors to vasodilation 
could be superfused before and after stimulation to block hypothesized pathways. 
 
A B 
Figure 36: Poor Vessel Images. Examples of poor image quality of vessel due to (A) 
vascularization due to inflammatory response (B) overlying adipose tissue due to larger 
or older mouse 
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AIM 2: DEVELOPMENT OF FUNCTIONAL VASODILATION PROTOCOL FOR 
PHARMACOLOGICAL DELIVERY 
 In the lab, there currently is no way to electrically stimulate the gracilis muscle 
while delivering pharmacologic agents to the area. This protocol solves the problem of 
not being able to add drugs to the preparation through mineral oil. By adding the drugs to 
a superfusion solution, pharmacological agents can be easily added to the preparation. 
The goal was to create a consistent protocol with minimal dilation caused by the 
superfusion solution. A superfused functional vasodilation protocol would allow for 
further research into the impact of ischemia on the cellular pathways controlling 
vasodilation. Pharmacological factors could be added to the superfusion solution to 
enhance or inhibit factors in the cellular pathways, creating an opportunity to assess 
causal relationships.  Irrigating the exposed tissue with an isotonic, degassed solution 
allows for the delivery of pharmacological agents while preventing desiccation and 
minimizing oxygen diffusion.  
 The results of the protocol showed a significant increase in diameter, 
approximately 75%, after the addition of the superfusion solution to the preparation. 
Because of the pre-dilation, it creates a higher resting diameter for the artery, reducing its 
maximal dilation potential. The intention of the protocol development was to minimize 
this increase in response to the superfusion solution and increase the consistency of the 
data collection. Consistency is desired due to the variable nature of the surgical model 
that is used. Dr. Steven Segal of the University of Missouri, a veteran in superfusion 
protocols, was consulted during this protocol development and made some 
recommendations on how to improve the superfusion experimental protocol. 
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Aim 2: Completed Modifications 
 One of the first controls put into place was monitoring the pH of the physiological 
salt solution, because changes in pH can alter vessel tone and oxygen exchange with 
tissues [1]. Another recommendation was bubbling the solution with CO2:N2 gas before 
superfusing it over the hindlimb. N2 gas is used because helps deoxygenate the solution. 
This is important because oxygen transport from the atmosphere directly to skeletal 
muscle will cause the smooth muscle to constrict [2]. The combination of these 
modifications produced an interesting result. Right after the PSS was mixed, the pH was 
measured and averaged 7.9; after the PSS was bubbled, pH decreased to 7.1. Both of 
these values are above and below the desired pH values (7.30 - 7.35), respectively. The 
pH was then measured after it had flowed through the circuit and was within desired 
values, this was possibly due to the carbon dioxide diffusion out of the solution during 
the time it was in the circuit. Efforts were made to pH balance the solution before adding 
it to the irrigation circuit; however this did not produced positive results. Further, 
application of varying pH levels, demonstrated that a change in pH was not the cause of 
the resting vasodilation. 
 In addition to pH, vascular tone is also affected by temperature. Thus, another 
modification was to vary the temperature and flow rate of the solution. Previous 
investigators maintained the PSS at 35 ºC with a flow rate of ~2mL·min-1  [47]. Adjusting 
the syringe heater the flow rate could both change the temperature due to the gain and 
loss of temperature through the circuit, respectively. Great efforts were taken to minimize 
this temperature loss by insulating the circuit, but a temperature loss of about 10 ºC from 
the beginning to end of the circuit was still observed. Both the temperature and flow rate 
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changed throughout the experiment and extra care was taken to maintain both of these 
values close to preferred ranges. Dr. Segal recommended that a temperature of 37 ºC 
should be used. Unfortunately, a similar loss of vessel tone was seen at both high (40 ºC) 
and low (30 ºC) temperatures.  
Given that changes in PSS properties did not affect vascular tone, it was also 
speculated that the shear stress between the surface of the profunda femoris artery and the 
intravital microscope lens caused vasodilation. To test this, the intravital microscope was 
removed and the vessel was observed with a stereo light microscope, which has a ~10 cm 
working distance and does not directly contact the tissue. Unfortunately, altering the flow 
conditions of the PSS over the profunda femoris did not impact the resting vasodilation.  
 After eliminating temperature and pH, other variables that were analyzed were the 
freshness of the solution and the cleanliness of the superfusion circuit equipment. This 
recommendation was made because the salts in the solution and superfusion circuit 
precipitate in the solution and adsorb in the circuit, causing changes in the concentration 
of the different compounds. Due to the potential buildup of salts in the circuit, the dishes 
cleaning protocol was changed, implementing a different rinse into the process, and 
changing out all of the tubing that was used with new tubing. It was also determined that 
a piece of metal in the circuit was corroding from the acid rinse during the cleaning 
protocol. The metal was replaced with a plastic piece to prevent this corrosion. Again, no 
difference in vessel tone was observed with these changes. 
 Since precipitated salts were not causing the problem, the final variable to change 
was the actual salts used in the solutions. The compounds used were the same; however 
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the product numbers were different from those of Dr. Segal’s group. Even after changing 
to the same product numbers, similar results were seen with loss of vessel tone 30 
minutes after the superfusion solution was applied. 
 
Aim 2: Future Recommended Modifications 
 Recommended modifications involve gaining more control of the superfusion 
circuit. The following variables changed throughout the experiment: gas bubbling rate, 
flow rate and temperature. Often times during the experiment, the rate of bubbling in the 
solution was variable. To solve this problem the bubbling rate of the superfusion solution 
needs to be higher to prevent a decrease in bubbling rate that was seen. The level of 
superfusion liquid was kept at 60 mL in the syringe heater, leaving a small volume for the 
bubbling solution. Decreasing this volume to 50 mL in the syringe will allow more room 
for bubbling at a higher rate without the solution spilling out of the top of the syringe. To 
maintain temperature and flow rate, flow rate must be more accurately controlled. 
Currently, flow rate is monitored through compressing a tube with a screw clamp. It is 
difficult to obtain and maintain using this method. 
 Flow over the profunda femoris artery must also be consistent. Often, the 
intravital microscope prevented flow over the artery if it was depressed too much. The 
positive effect was lack of vasodilation of the artery, however if a drug was in the 
superfusion solution, it had no effect on the artery. To combat this problem, a different 
intravital microscopy method is needed. This could be accomplished by using a 
microscope with a larger working distance, such as a compounded reflected light 
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microscope; so more space could be put between the microscope and the profunda 
femoris artery. 
The development of a consistent superfused functional vasodilation protocol is 
imperative for future understanding of endothelial dysfunction due to ischemic injury. 
The ability to target and inhibit or enhance specific cellular mechanisms during a 
functional vasodilation experiment is essential for determining the impact of ischemia on 
this process. 
 
AIMS 3 AND 4: IMPACT OF ISCHEMIA ON CELL DEPENDENT DILATION AND 
CONSTRICTION  
 Previous work has demonstrated impaired vasodilation in arterioles, but the effect 
of ischemia on feed arteries is unknown. Understanding how ischemia affects feed 
arteries is important because feed arteries play a critical role in determining tissue blood 
flow. A healthy artery has the ability to vasodilate and vasoconstrict in order to ensure the 
homeostasis of oxygen and other nutrients of the downstream tissues. In response to acute 
ischemia/hypoxia, vessels dilate to increase the blood flow to the affected area. 
Unfortunately, chronic ischemia leads to vasodilatory dysfunction. Ischemic arterioles in 
the lower leg have impaired functional vasodilation, which could be explained by 
impaired endothelial-dependent dilation [69, 70]. Similar results were found in rat 
collateral arteries in vitro [71]. In both studies, exercise restored endothelial function. 
Due to this result, it was hypothesized that post-resected mice would present a similar 
endothelial dysfunction and dilate less to ACh than SNP. 
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Aim 4: Possible Smooth Muscle Dysfunction 
 Due to the fact that ACh and SNP produced similar results and there was no 
significant difference between the two treatments, smooth muscle dysfunction is the best 
reason for this result. Since only three pharmaceuticals were used in the experiment, 
further research is needed to discover what mechanism is dysfunctioning. One 
explanation for why smooth muscle dependent process would be impaired is due to the 
pressure in the profunda femoris artery. The surgical removal of the femoral artery, 
which feeds the profunda femoris, is assumed to decrease pressure the ischemic side. 
Knowing the pressure could help further differentiate the role of cellular dysfunction in 
smooth muscle cells versus altered vasodilation due to changes in hemodynamics. There 
could be a biochemical difference in the smooth muscle causing dysfunction as well. 
 To better understand the resulting pathology of the resection surgery, further 
research must be done to fully rule out endothelial dysfunction. In addition to using 
endothelial-dependent vasodilators, the impact of ischemia on the endothelium can be 
assessed by damaging or removing the endothelium. The endothelium can be damaged by 
perfusing an air bubble through the vessel or by using an intravascular dye that heat-
injures the endothelium following excitation [47].  
Vasoconstriction was also analyzed to fully understand the dynamic range of the 
artery. Previous groups have shown an increased vasoconstrictive response by ischemic 
limbs [51] while others have shown a reduction in sympathetic tone with chronic 
ischemia [41]. In this study, both groups responded similarly to neuroepinephrine. This 
discrepancy could have contributed to the difficulty in measuring the vessel when it was 
vasoconstricted, as the differences in such a small diameter were difficult to differentiate 
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due to the microscope resolution. Also, due to the fact that the previous demonstration of 
enhanced constriction was performed with human tissue, there are several comorbidities 
involved in the patient when compared to the mouse that could explain this difference, 
such as hypertension. 
 
Differences between Superfusion and Functional Vasodilation 
 There are some observed differences between the functional vasodilation and 
superfusion results. The measured resting values of the ischemic limbs are different. For 
both the young and adult mice in the first aim, they are around 100 µm. In the fourth aim, 
the resting diameter is around 80 µm.  
First, the differences in ischemic resting diameter will be addressed. In previous 
work from Matt Yocum, possible causes of an increased diameter was a decreased time 
between dissection and measurement, and contact between the MicroScan tip and the 
profunda femoris artery [58]. These recommendations were understood before both aims. 
When a higher resting diameter was noticed, more time was added to the timer (more 
than 30 minutes) and great care was taken to move the MicroScan as high as possible to 
prevent contact between it and the underlying tissue.  
 One possible hypothesis to this observed difference in resting values could be the 
difference in surgical equipment and technique used between the two aims. The cautery 
used in the first aim was old and inconsistent and was replaced with brand new cautery 
after Aim 1 was completed. This created a more consistent heat profile that burned 
through the artery faster, allowing for more visible artery length 14 days later. There was 
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also a difference in technique that was used during dissection before the superfusion 
experiment in aim 4. Microdissection scissors were used to carefully cut away the 
connective tissue above the profunda femoris artery, as opposed to careful blunt 
dissection that was previously used. This could have caused less stretching of the artery, 
allowing for less distress to the artery and surrounding tissue. 
 In summary, ischemia impairs vascular reactivity however it remains unclear if it 
is endothelial dysfunction or smooth muscle dysfunction. The proposed data implies 
smooth muscle dysfunction; however more research needs to be completed to fully rule 
out endothelial dysfunction.  
 
FINAL CONCLUSIONS 
 This study has shown that ischemia and age significantly affect vascular function. 
Determining the cause of this dysfunction requires additional studies and protocol 
improvements. This leads to further possibilities of research with this model. First a few 
key problems need to be addressed. 
The resection model proves to be difficult due to the current experimental setup. 
This model could become a more viable option if the surgical protocol did not involve 
cautery, a method that as stated previously is hard to control with current equipment. 
Also, using a microscope that allows for a larger focal distance that restricts tissue 
contact will help control the model to allow for more consistent results. Digital calipers 
will also provide a more controlled and consistent method to measure arterial diameters. 
Once these problems are addressed future experimental methods can be attempted. 
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As stated in the introduction, mice have a large number of transgenic options to 
allow experiments that test causal relationships. Surgical methods also provide 
opportunities to look at the possibility of endothelial dysfunction. Superfusion protocols 
with different drugs such as inhibitors can help address specific cellular pathway 
dysfunctions.  Also, with improvements made in superfusion, the effects of age using 
cell-specific vasoactive agents can be addressed. Exercise is also a possible treatment to 
be attempted, as previous research has showed improvement in endothelial function [41, 
70, 71] following exercise. It is still unclear what specifically impairs vascular function in 
ischemic conditions; it is the goal of this research to solve those questions. There has 
been a history of efficacy of therapies in animal models and disappointing results seen in 
randomized patient trials, perhaps the current way this model is used is the answer to this 
problem. 
To better understand the current model and its dysfunction, age must be addressed 
with the superfusion protocol to determine if endothelial dysfunction exists in adult mice. 
Also, old mice, that could present more dysfunction than young mice, should be 
examined. Finally, different pharmaceuticals such as inhibitors need to be used in the 
superfusion setup to better differentiate between endothelial dysfunction and smooth 
muscle dysfunction.  
With the knowledge gained from these results, it is shown that ischemia and age 
significantly impairs vasodilation in a feed artery. By improving vasodilation in patients 
with ischemia, blood flow could be partially restored. More specifically, therapies 
targeting smooth muscle could prove more effective.
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APPENDIX A 
RESECTION PROTOCOL 
 
Figure 37: Resection Protocol 
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APPENDIX B 
DUAL FUNCTIONAL VASODILATION PROTOCOL
 
Figure 38: Functional Vasodilation Protocol (Page 1) 
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Figure 39: Functional Vasodilation Protocol (Page 2) 
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APPENDIX C 
SUPERFUSION PROTOCOL
 
Figure 40: Superfusion Protocol (Page 1) 
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Figure 41: Superfusion Protocol (Page 2) 
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APPENDIX D 
SUPERFUSED FUNCTIONAL VASODILATION PROTOCOL 
 
Figure 42: Superfused Functional Vasodilation Protocol (Page 1) 
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Figure 43: Superfused Functional Vasodilation Protocol (Page 2) 
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APPENDIX E 
SDF IMAGING ANALYSIS USING AVA SOFTWARE 
In order to produce accurate measurements, the MicroScan was first calibrated 
according to the manufacturers specifications. For the data collection portion, the 
MicroScan was placed on a horizontal plane. This was usually accomplished through 
secure placement in the boom stand. It was also important for the MicroScan to not be in 
contact with the profunda femoris, but to be as far above it as possible while keeping the 
vessel in focus. 
 In order to record a video, AVA 3.0 was first opened which led to a main menu 
screen (Figure 44). After selecting the “data” button, the specific folder where the videos 
were saved was chosen. The “capture” button was then selected and specific information 
regarding the experiment was entered (mouse tag, sham or exp, etc.). Videos were taken 
for 10 seconds by pressing the “start capture” button. These videos were automatically 
saved in the folder that was determined earlier in the process. 
 For data analysis, selecting the “analysis” button opened a video file (Figure 45). 
Once the specific video file was chosen, sliding the white bars at the bottom of the screen 
chose the number of frames. Then, the “stabilize video” button was chosen and the result 
was a video file that stabilized and accounted for the breathing of the mouse. Then, the 
outline of the profunda femoris artery was carefully traced and the average diameter was 
recorded. This process of analysis was repeated for each video file and was performed the 
same way each time. 
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Figure 44: AVA  
(A) Front screen where options to create folders [Settings], create videos for analysis 
[Capture] and analyze videos to create data points [Analysis]. (B) Once selecting 
“Capture” the menu allows for creation of videos with [Start capture] 
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Figure 45: Image Analysis  
(1) Stabilize image before analysis (2) Draw outline of artery (3) Example of artery 
outline (4) Delete outline of drawing if not accurate on vessel wall (5) Average diameter 
measurement 
 
